Recent Updates
Recently added Catalysts
TEVA

The following tables present revenues, expenses and profit for each segment for the years ended

Thursday, April 18, 2024 1 min read
Key Takeaway: The following tables present revenues, expenses and profit for each segment for the years ended December 31, 2023 and 2022, and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023: United States Segment Year ended December 31,

Full Press Release Details

The following tables present revenues, expenses and profit for each segment for the years ended December 31, 2023 and 2022, and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023:
United States Segment
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Revenues $ 7,731 $ 7,003 $ 2,266 $ 1,896 $ 1,892 $ 1,677
Gross profit 4,310 3,734 1,444 1,060 1,017 789
R&D expenses 604 485 144 156 156 149
S&M expenses 938 879 238 243 250 207
G&A expenses 378 440 90 93 101 95
Other income ( 5 ) ( 3 ) ( 1 ) ( 2 ) ( 1 )
Segment profit* $ 2,394 $ 1,934 $ 974 $ 571 $ 511 $ 338
Europe Segment
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Revenues $ 4,837 $ 4,525 $ 1,344 $ 1,146 $ 1,163 $ 1,184
Gross profit 2,726 2,700 783 648 640 655
R&D expenses 220 213 52 62 53 53
S&M expenses 767 748 203 184 194 187
G&A expenses 263 246 67 66 61 70
Other income ( 2 ) ( 3 ) ( 1 )
Segment profit* $ 1,478 $ 1,496 $ 461 $ 338 $ 334 $ 345
International Markets Segment
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Revenues $ 2,351 $ 2,352 $ 601 $ 591 $ 578 $ 581
Gross profit 1,160 1,224 299 293 283 285
R&D expenses 104 119 24 30 23 27
S&M expenses 487 467 134 116 125 113
G&A expenses 142 154 37 33 34 38
Other income ( 39 ) ( 54 ) ( 4 ) ( 2 ) ( 31 ) ( 1 )
Segment profit* $ 465 $ 538 $ 109 $ 117 $ 132 $ 108
The following tables present revenues by major products and activities for each segment for the years ended December 31, 2023 and 2022 and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023:
United States Segment
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Generic products 3,138 3,155 667 839 884 747
AJOVY 211 210 57 56 52 46
AUSTEDO 1,225 963 408 339 308 170
BENDEKA and TREANDA 237 309 52 56 67 62
COPAXONE 297 359 72 98 56 71
Anda 1,577 1,471 394 367 392 424
Other 1,047 536 616 142 131 158
Total $ 7,731 $ 7,003 $ 2,266 $ 1,896 $ 1,892 $ 1,677
Europe Segment
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Generic products 3,664 3,466 938 886 909 932
AJOVY 160 124 45 41 39 36
COPAXONE 231 268 56 55 60 59
Respiratory products 265 273 70 61 66 68
Other 516 393 234 104 89 89
Total $ 4,837 $ 4,525 $ 1,344 $ 1,146 $ 1,163 $ 1,184
International markets Segment
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Generic products 1,932 1,980 506 470 478 477
AJOVY 63 42 19 18 14 13
COPAXONE 63 64 12 16 17 17
Other 293 266 64 87 69 74
Total $ 2,351 $ 2,352 $ 601 $ 591 $ 578 $ 581
The following tables present revenues by major products and activities for Canada for the years ended December 31, 2023 and 2022 and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023:
Canada
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Generic products 337 394 86 89 84 77
AJOVY 20 7 6 6 5 3
AUSTEDO - - - - - -
BENDEKA and TREANDA 4 7 1 1 1 1
COPAXONE 23 28 5 5 8 5
Anda - - - - - -
Other 9 13 1 4 1 2
Total $ 393 $ 449 $ 99 $ 106 $ 99 $ 89
Tags: TEVA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Apr 18, 2024